29 mayo 2023
Manejo del trauma en pacientes embarazadas
10 mayo 2023
La patofisiología del síndrome coronario agudo
El síndrome coronario agudo (SCA) es la forma más grave de la enfermedad isquémica cardiaca. Aunque se sabe que está causado por trombosis de la placa aterosclerótica o por otras causas, su mecanismo fisiopatológico aún no se comprende del todo, por lo que es una cuestión en constante revisión. Actualmente, los principales mecanismos fisiopatológicos que se conocen incluyen la ruptura de la placa aterosclerótica, la erosión de la placa, los nódulos calcificados, y otras causas no ateroscleróticas como el vasoespasmo coronario y el puente miocárdico. Estos, en ocasiones, se solapan y coexisten en el mismo paciente. La complejidad del mecanismo patofisiológico, y su importancia para el diagnóstico y el tratamiento del SCA, ha llevado a los autores de este artículo, cuatro cardiólogos del hospital de la Universidad de Tongji (Shanghai, China), a realizar una puesta al día de la cuestión. Enlace de descarga: bit.ly/42CxAzM. Acute coronary syndrome (ACS) is the most severe form of ischemic heart disease. Although it is caused by atherosclerotic plaque thrombosis or nonatherosclerotic causes, its pathophysiological mechanism of ACS is not fully understood, and its concept is constantly updated and developed. At present, the main pathophysiological mechanisms include plaque rupture, plaque erosion, calcified nodules (CN) and non-atherosclerotic causes such as coronary vasospasm and myocardial bridging (MB). These mechanisms may overlap and coexist in some ACS patients. The complexity of the pathophysiological mechanism of ACS is complex, and its great significance for the diagnosis and treatment of ACS, leaded to the authors of this review article, four cardiologists from Tongji’s University hospital (Shanghai, China), to update the status of the topic to provide new thoughts on the pathogenesis, diagnosis and treatment of ACS. Download link: bit.ly/42CxAzM.
04 mayo 2023
La maniobra de Chandy
25 abril 2023
Shock hemorrágico en trauma: protocolos de actuación.
30 marzo 2023
Protocolo de liberación del ventilador mecánico
https://drive.google.com/file/d/12t2MMkUAdImaSS2cZMKnhmQFTMrrJdiW/view?usp=sharing
25 marzo 2023
Analgesia multimodal en el paciente crítico
emprana. Los autores de este artículo publicado en
la Revista Chilena de Anestesia, intensivistas y anestesistas de varios
hospitales de México y el Hospital Clínic de Barcelona (España), revisan lo
publicado al respecto y hacen un completo repaso que incluye las escalas de
valoración del dolor y el mecanismo de acción de los fármacos y propone un
algoritmo para el manejo de la analgesia en las UCI. Puedes descargarlo en el siguiente enlace: https://drive.google.com/file/d/1GXBbF9kdJ3S8_KPAK9KupCbJVHZWBo_3/view?usp=sharing.
22 marzo 2023
Eficacia de la maniobra de Valsalva modificada para revertir una TSV
The Valsalva manoeuvre is an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare in practice (5–20%), necessitating the use of other treatments including adenosine or even electrical therapies. The authors of this article published in 2015, emergency doctors and cardiologists from England, propose a modified manoeuvre and evaluate its effectiveness in a randomized study with 433 participants enrolled. They find that the conversion rate to a sinus rhythm is higher (43% vs. 17%) than using the standard Valsalva manoeuvre and propose, consequently, to use the modified Valsalva instead of the classical one. You can see, in the video attached, how to do a modified Valsalva manouevre, and download the article in the following link: https://drive.google.com/file/d/1sUHfi1VQXaUX1J298hN8pYdM1USdeIxZ/view?usp=sharing
03 marzo 2023
Utilización de la desescalada verbal para reducir la contención mecánica durante los traslados no voluntarios en ambulancia
14 febrero 2023
Evaluación de la eficacia y la seguridad del uso de la TAFCN en pacientes ancianos con IRA
High-flow nasal cannula therapy (HFNC) is recognized as the first therapeutic option in patients with hypoxemic acute respiratory failure (ARF), and there is evidence of its efficacy also in patients with hypercapnic ARF. There is a group of elderly (more than 75 years) patients with ARF who, after receiving medical treatment and conventional oxygen therapy, remain with dyspnoea and refractory hipoxemia. Many of them, due to factors such as age, severe comorbidity, functional capacity or willingness, are not candidates to be admitted to the intensive care unit. This study, developed by a group of emergency doctors from Spain, newfangled because the subjects were all elderly patients as defined above, included 200 patients along a year (mean age, 83 years), and concludes that HFNC is an effective and safe option in these patients as a therapeutic ceiling, with benefits regarding to oxygenation, respiratory rate and dyspnoea but also to comfort. Download link: https://drive.google.com/file/d/1Ckgyo_cBvbWAa0e9VsB5FMaweAtUMQnx/view?usp=sharing
06 febrero 2023
Todo lo que debes saber sobre la desreanimación (deresuscitation)
En este contexto surgió en 2014 el término, de difícil traducción al español, desreanimación o desresucitación (deresuscitation), que se define como la eliminación activa de fluidos de un paciente con sobrecarga de fluidos, bien mediante fármacos o por ultrafiltración. Relacionado con él está el de “desescalada”, que se relaciona con la reducción progresiva de la cantidad de fluidos que se administran a un paciente. El artículo que traemos hoy, publicado en 2022 por cinco intensivistas de diferentes países, pretende (y creemos que consigue) explicar todo lo que debemos conocer sobre los efectos adversos de la administración excesiva de fluidos y cómo y cuándo comenzar, y finalizar, la desreanimación. Enlace de descarga: https://drive.google.com/file/d/1Jgy-MbgxClDYF-9b8bUuwi6p3k-O_tGx/view?usp=sharing
While fluid administration
is one of the most common therapeutic interventions in critical care, it’s
not harmless at all. Fluids should be regarded as drugs with specific
indications, contraindications, and potential adverse effects. The renewed
concept of “fluid stewardship”, analogous to antibiotic stewardship, focusses
on the 4 D’s (drug, dose, duration, and de-escalation), the 4 questions (when
to start and when to stop fluid therapy, and when to start and when to stop
fluid removal), the 4 indications (resuscitation, maintenance, replacement and
nutrition), and the conceptual ROSE model
describing 4 fluid phases (resuscitation, optimization, stabilization and
evacuation).
The term deresuscitation was coined in 2014 and defined as active fluid removal in patients with fluid overload using drugs and/or ultrafiltration (UF). The term ‘de-escalation’ relates more to reducing the amount and rate of previously started fluid administration. The article web ring today, published in 2022 for five intensive care doctors from different countries, pretends (succesfully, we think) to explain all we should know about the adverse effects of the fluid overload and how and when to start (and finish) the deresuscitation. Download link: https://drive.google.com/file/d/1Jgy-MbgxClDYF-9b8bUuwi6p3k-O_tGx/view?usp=sharing






.png)





.png)




.png)


.png)
